Ken Griffin Alkermes Plc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$23.01 - $28.55 $11,505 - $14,275	500 Added 2.78%	18,500 $517,000
Q2 2024 Aug 14, 2024	SELL	$23.21 - $27.24 $188,001 - $220,644	-8,100 Reduced 31.03%	18,000 $433,000
Q1 2024 May 15, 2024	BUY	$26.4 - $32.56 $47,520 - $58,608	1,800 Added 7.41%	26,100 $706,000
Q4 2023 Feb 14, 2024	SELL	$23.37 - $28.68 $588,924 - $722,736	-25,200 Reduced 50.91%	24,300 $674,000
Q3 2023 Nov 14, 2023	BUY	$27.17 - $31.97 $116,831 - $137,471	4,300 Added 9.51%	49,500 $1.39 Million
Q2 2023 Aug 14, 2023	SELL	$28.34 - $33.63 $136,032 - $161,424	-4,800 Reduced 9.6%	45,200 $1.41 Million
Q1 2023 May 15, 2023	SELL	$25.31 - $29.02 $9.55 Million - $11 Million	-377,500 Reduced 88.3%	50,000 $1.41 Million
Q4 2022 Feb 14, 2023	BUY	$21.94 - $26.24 $8.61 Million - $10.3 Million	392,400 Added 1117.95%	427,500 $11.2 Million
Q3 2022 Nov 14, 2022	SELL	$22.0 - $31.87 $123,200 - $178,472	-5,600 Reduced 13.76%	35,100 $784,000

361

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.58B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.